Biomarker for idiopathic inflammatory myopathy and application thereof

By using anti-HDGFL1 antibody as a biomarker, the diagnostic challenge of MSA-negative idiopathic inflammatory myopathy has been solved, enabling accurate diagnosis and prognostic assessment. It also identifies other disease subgroups in the myositis spectrum, supporting early treatment and prognostic judgment.

CN118962150AActive Publication Date: 2024-11-15PEKING UNION MEDICAL COLLEGE HOSPITAL

Patent Information

Application Number
CN202411061100.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-15
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Current technologies are insufficient for the effective diagnosis and assessment of MSA-negative idiopathic inflammatory myopathy, leading to difficulties in diagnosis and prognosis.

Method used

Anti-HDGFL1 antibody was used as a biomarker. The level of anti-HDGFL1 antibody in serum samples was detected by immunofluorescence assay, radioimmunoassay, colloidal gold method, antibody screening, complement fixation or enzyme-linked immunosorbent assay. It was used for the diagnosis, prognostic assessment and disease classification of idiopathic inflammatory myopathy.

Benefits of technology

It provides accurate diagnosis and prognostic assessment of idiopathic inflammatory myopathy in the case of MSA negativity, helps identify other disease subgroups, and supports early treatment and prognostic judgment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118962150A_ABST
    Figure CN118962150A_ABST
Patent Text Reader

Abstract

The invention provides a biomarker for idiopathic inflammatory myopathy and application of the biomarker. The biomarker is an anti-HDGFL1 antibody. The invention further discloses an application of the anti-HDGFL1 antibody as a biomarker of idiopathic inflammatory myopathy and an application of an anti-HDGFL1 antibody detection agent in preparation of products related to diagnosis of idiopathic inflammatory myopathy. Kits and systems for diagnosing idiopathic inflammatory myopathy, assessing the prognosis of patients with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy. Effective diagnosis, treatment, prognosis evaluation and disease typing of patients with serum myositis specific autoantibody negative idiopathic inflammatory myopathy are realized through the anti-HDGFL1 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to biomarkers of idiopathic inflammatory myopathy and applications thereof. Background Art

[0002] Idiopathic inflammatory myopathy (IIM) is a group of autoimmune diseases that mainly affect skeletal muscles and are often accompanied by multiple visceral organ involvement such as muscle weakness, rash, and interstitial lung lesions. Myositis specific autoantibody (MSA) is crucial for the diagnosis and treatment of IIM. Existing studies have shown that up to 60%-80% of IIM patients have MSA. Each MSA seems to be associated with a specific clinical phenotype and is almost only present in IIM patients. For example, patients with positive MDA5 antibodies often have rapidly progressive interstitial lung lesions, while TIF1-γ antibodies are associated with an increased risk of cancer. However, according to statistics, 20%-30% of IIM patients have no known myositis-specific autoantibodies detected, that is, MSA-negative IIM patients, which causes great trouble for the diagnosis and prognosis of IIM and disease progression. Therefore, for MSA-negative IIM patients, exploring new myositis autoantibodies will help identify other disease subgroups in the myositis spectrum, and will be of great significance for the early diagnosis and treatment of IIM, prognosis judgment, and potential mechanism research. Summary of the invention

[0003] The object of the present invention is to provide a biomarker for characterizing idiopathic inflammatory myopathy and its application, so as to effectively diagnose, treat, monitor idiopathic inflammatory myopathy, evaluate its prognosis and classify the disease, especially for MSA-negative IIM patients.

[0004] In order to achieve the above-mentioned purpose, the present invention adopts the following technical solutions.

[0005] According to a first aspect of the present invention, there is provided a use of an anti-HDGFL1 (Hepatoma derived growth factor-like 1) antibody as a biomarker for idiopathic inflammatory myopathy.

[0006] Further, the use of anti-HDGFL1 antibody as a biomarker for characterizing idiopathic inflammatory myopathy in myositis-specific autoantibody MSA-negative idiopathic inflammatory myopathy patients.

[0007] Furthermore, the use of anti-HDGFL1 antibody as a biomarker for characterizing idiopathic inflammatory myopathy in patients with MSA-negative idiopathic inflammatory myopathy in the preparation of products related to the diagnosis of idiopathic inflammatory myopathy.

[0008] According to a second aspect of the present invention, there is provided a use of an anti-HDGFL1 antibody detection agent in the preparation of products related to the diagnosis of idiopathic inflammatory myopathy.

[0009] Furthermore, products related to the diagnosis of idiopathic inflammatory myopathy include products for diagnosing idiopathic inflammatory myopathy, products for evaluating the prognosis of patients with idiopathic inflammatory myopathy, or products for determining the classification of idiopathic inflammatory myopathy.

[0010] Furthermore, products related to the diagnosis of idiopathic inflammatory myopathy include at least one of reagents, kits, and chips.

[0011] Furthermore, the anti-HDGFL1 antibody detection agent includes a reagent for detecting the expression level of the anti-HDGFL1 antibody by at least one of immunofluorescence assay, radioimmunoassay, colloidal gold method, antibody screening, complement fixation, and enzyme-linked immunosorbent assay.

[0012] According to a third aspect of the present invention, there is provided an anti-HDGFL1 antibody detection agent for use in preparing a diagnostic product for diagnosing idiopathic inflammatory myopathy, assessing the prognosis of a patient with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy by the following method, the method comprising the following steps:

[0013] Provide a serum sample from the individual to be tested;

[0014] The levels of anti-HDGFL1 antibodies in serum samples were measured;

[0015] According to the measured anti-HDGFL1 antibody level, diagnosis, prognosis assessment or disease typing is performed on the individual to be tested;

[0016] Among them, diagnosing the individual to be tested means determining whether the individual to be tested is a patient with idiopathic inflammatory myopathy who is negative for myositis-specific autoantibodies MSA;

[0017] Among them, the prognostic evaluation of the individual to be tested refers to the evaluation of the prognostic status of patients with MSA-negative idiopathic inflammatory myopathy;

[0018] Among them, disease typing of the individual to be tested refers to evaluating the clinical phenotype of patients with MSA-negative idiopathic inflammatory myopathy and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0019] According to a fourth aspect of the present invention, there is provided a kit for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of patients with idiopathic inflammatory myopathy or determining the typing of idiopathic inflammatory myopathy, comprising an anti-HDGFL1 antibody detection agent.

[0020] According to a fifth aspect of the present invention, there is provided a method for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of a patient with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy:

[0021] Provide a serum sample from the individual to be tested;

[0022] The levels of anti-HDGFL1 antibodies in serum samples were measured;

[0023] According to the measured anti-HDGFL1 antibody level, diagnosis, prognosis assessment or disease typing is performed on the individual to be tested;

[0024] Among them, diagnosing the individual to be tested means determining whether the individual to be tested is a patient with idiopathic inflammatory myopathy who is negative for myositis-specific autoantibodies MSA;

[0025] Among them, the prognostic evaluation of the individual to be tested refers to the evaluation of the prognostic status of patients with MSA-negative idiopathic inflammatory myopathy;

[0026] Among them, disease typing of the individual to be tested refers to evaluating the clinical phenotype of patients with MSA-negative idiopathic inflammatory myopathy and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0027] According to a sixth aspect of the present invention, there is provided a system for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of a patient with idiopathic inflammatory myopathy, or determining the classification of idiopathic inflammatory myopathy, comprising:

[0028] A sample acquisition module, which is used to provide a serum sample from an individual to be tested;

[0029] A sample detection module, which is used to determine the level of anti-HDGFL1 antibodies in a serum sample;

[0030] An analysis and evaluation module, which is used to diagnose, evaluate the prognosis or perform disease typing on the individual to be tested according to the determined level of anti-HDGFL1 antibodies;

[0031] Among them, diagnosing the individual to be tested means determining whether the individual to be tested is a patient with MSA-negative idiopathic inflammatory myopathy;

[0032] Among them, the prognostic evaluation of the individual to be tested refers to the evaluation of the prognostic status of patients with MSA-negative idiopathic inflammatory myopathy;

[0033] Among them, disease typing of the individual to be tested refers to evaluating the clinical phenotype of patients with MSA-negative idiopathic inflammatory myopathy and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0034] Compared with the prior art, the present invention has the following significant technical effects:

[0035] (1) The present invention provides a biomarker for characterizing idiopathic inflammatory myopathy, which can be used for the diagnosis, prognosis assessment and disease classification of idiopathic inflammatory myopathy.

[0036] (2) The present invention can be used as a supplementary diagnostic biomarker when MSA cannot be used to diagnose patients with idiopathic inflammatory myopathy, that is, when the patient is MSA negative.

[0037] (3) The present invention helps to further identify other disease subgroups in the myositis spectrum, which is of great significance for the early diagnosis and treatment, prognosis and potential mechanisms of IIM. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is a distribution heat map of the SNR values ​​of the top 50 candidate target proteins in Example 1, which are arranged in descending order of difference fold, in the MSA seronegative group (MSANeg), the MSA seropositive group (MSAPos), systemic lupus erythematosus patients (SLE), systemic sclerosis patients (SSc) and the healthy control group (HC);

[0039] Figure 2 is the fluorescence signal of HDGFL1 protein in the MSA seronegative group (MSA-) and the healthy control group (HC) in Example 1;

[0040] Figure 3 These are the fluorescent band images of the MSA serum negative group (MSA-) and the healthy control group (HC) in Example 2. DETAILED DESCRIPTION

[0041] In order to enable those skilled in the art to better understand the scheme of the present invention, the present invention is further described in detail below. The specific implementation methods listed below are only for describing the principles and features of the present invention. The examples are only used to explain the present invention and are not intended to limit the scope of the present invention. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in the field without creative work are within the scope of protection of the present invention.

[0042] In one embodiment of the present invention, a use of an anti-HDGFL1 antibody as a biomarker for idiopathic inflammatory myopathy is provided.

[0043] HDGFL1 is a nuclear protein containing 251 amino acids and a molecular weight of approximately 27 kDa, which may activate double-stranded DNA binding, transcriptional co-regulator activity, and participate in the transcriptional regulation of RNA polymerase II. The inventors discovered for the first time that anti-HDGFL1 antibodies can be used to characterize idiopathic inflammatory myopathy, especially in patients with MSA-negative IIM. In the present invention, anti-HDGFL1 antibodies refer to immunoglobulins that are spontaneously produced in the body of a target subject (e.g., an individual to be tested who is MSA-negative) or produced under stress in an external environment, and are mainly present in body fluids such as serum, which can specifically bind to and react with the HDGFL1 protein. Specifically, anti-HDGFL1 antibodies refer to specific autoantibodies against the HDGFL1 protein. In addition, since the serum of healthy people does not contain anti-HDGFL1 antibodies, and for some patients with idiopathic inflammatory myopathy, especially MSA-negative IIM patients, there is no report of the presence of autospecific antibodies in their bodies, anti-HDGFL1 antibodies can be used as a biomarker to specifically characterize idiopathic inflammatory myopathy, thereby avoiding invasive damage to individuals during the diagnosis of myositis.

[0044] At the same time, the biomarkers characterizing idiopathic inflammatory myopathy provided by the present invention are helpful to further identify other disease subgroups in the myositis spectrum, and are of great significance for the early diagnosis and treatment, prognosis and potential mechanisms of idiopathic inflammatory myopathy.

[0045] In the present invention, an IIM patient may be a patient who is negative for MSA. For example, an IIM patient is an individual in whom MSA has not been detected or confirmed. Specifically, the individual is a human individual.

[0046] The inventors found that 33.3% of MSA-negative IIM patients had anti-HDGFL1 antibodies in their serum. Therefore, in the absence of effective MSA as a biomarker, which makes it impossible to diagnose the condition of IIM patients immediately and accurately, that is, when the patient is MSA-negative, anti-HDGFL1 antibodies can be used as a supplementary biomarker.

[0047] In one embodiment of the present invention, a method for screening and measuring biomarkers characterizing idiopathic inflammatory myopathy is provided, which specifically comprises the following steps:

[0048] (1) Chip pretreatment step: blocking the proteome chip;

[0049] (2) Chip incubation step: adding serum samples of patients with idiopathic inflammatory myopathy to the pretreated proteome chip for incubation, and then adding fluorescent secondary antibody for incubation after washing, and then washing to obtain the incubated proteome chip;

[0050] (3) Chip detection step: placing the incubated proteome chip in a chip scanner, reading the secondary antibody fluorescence signal on the incubated proteome chip, and saving the image;

[0051] (4) Data processing steps: Based on the saved images and the target protein coating array list of the proteomics chip, the analysis software GenePix Pro completes the pixel segmentation and extraction of each protein signal according to the protein spot matrix parameters in the proteomics chip. At the same time, manual screening is performed one by one to check the signal intensity of the corresponding signal points of all protein spots on the chip, and the signals are extracted for further analysis to obtain the detection signal and relative quantitative basis.

[0052] Specifically, before the chip pretreatment in step (1), a step of obtaining serum samples is also included. The serum samples include serum from patients with MSA-negative IIM, serum from patients with MSA-positive IIM, and serum from healthy individuals as controls. Preferably, the serum samples include serum from patients with MSA-negative IIM, serum from patients with MSA-positive IIM, serum from an autoimmune control group (serum from patients with systemic lupus erythematosus and patients with systemic sclerosis), and serum from healthy individuals as controls to increase the comparability between samples and the accuracy of target protein antibody screening.

[0053] Optionally, the serum sample can be a three-mixed, four-mixed or five-mixed serum sample.

[0054] Specifically, in the chip preprocessing step, a human proteome chip, such as HuProt TM Human proteome chip. Specifically, in the (1) chip preprocessing step, HuProt TM The human proteome chip was taken out from the -80°C refrigerator and put into a 4°C refrigerator for recovery. After one day, it was taken out and placed at room temperature for recovery and equilibrium for 1-2 hours. The balanced proteome chip was placed in an incubation box, and 5-10 ml of a 2-4% bovine serum albumin solution (BSA) was added as a blocking solution, and the chip was blocked for 1-2 hours at room temperature (20°C-25°C) using a shaker.

[0055] Specifically, in the chip pretreatment step, the blocking solution is removed from the blocked chip, a serum sample is added, and the chip is incubated at room temperature (20°C-25°C) for 1-3 hours, washed with a 0.2% tris(hydroxymethyl)aminomethane buffer (TBST) solution, and a fluorescent secondary antibody is added, and the chip is incubated in the dark for 1.0-1.5 hours. After the incubation, the chip is washed again with a 0.2% TBST solution, and then washed with ultrapure water.

[0056] Specifically, in the chip detection step, the fluorescence signal was read in the GenePix 4000 chip scanner and GenePix Pro software, and the Tiff image was saved. The parameters of the scanner were set as follows: the photomultiplier tube (PMT) was set to 600, the scanning intensity (ScanPower) was set to 10, and the scanning pixel was 10 μm.

[0057] Specifically, after the chip pretreatment step, preferably before the chip incubation, a chip quality assessment step is also included, in which the number of effective protein spots on the proteomics chip and the correlation of signal intensities between parallel protein spots are verified by hybridization of anti-GST antibodies with the proteomics chip.

[0058] Specifically, in the data processing step, the signal value corresponding to the target protein is the average signal-to-noise ratio (SNR) of the signal values ​​of two parallel points (F635medium / B635medium). When the value is greater than 2, it is determined that the autoantibody against the target protein can be detected. The cut-off point of each target protein is the signal value (F635mean) mean+3SD of the healthy control group, and the information of the positive rate of the immune reaction of each target protein on the serum sample and the proteome chip is calculated. The chip significance analysis is performed using high-throughput bioinformatics analysis tools to analyze the difference protein information between the groups, and the candidate target proteins are selected with a q value of less than 5% and a fold change greater than 3.

[0059] Finally, according to the fluorescence intensity and the target protein coated array list of the proteome chip, the antibody of the target protein with the highest fluorescence intensity is determined as the biomarker for characterizing idiopathic inflammatory myopathy.

[0060] In an embodiment of the present invention, the target protein on the proteome chip can capture the specific autoantibody in the serum sample of the IIM patient to form a target protein-specific autoantibody complex, and the specific autoantibody can bind to the second antibody (such as a fluorescent antibody) to form a target protein-specific autoantibody-second antibody complex. Since the second antibody carries a detectable fluorescent group, the level of the specific autoantibody can be determined by detecting the fluorescence intensity. The higher the fluorescence intensity, the higher the level of the specific autoantibody in the serum sample of the IIM patient. According to the target protein coated array list of the proteome chip, the target protein with the highest fluorescence intensity can be obtained, and the antibody against the target protein can be determined, thereby obtaining a biomarker characterizing idiopathic inflammatory myopathy.

[0061] In the present invention, the method for determining the biomarkers characterizing idiopathic inflammatory myopathy is implemented using a proteome chip, which is a high-throughput protein immunoassay analysis technology. Compared with traditional detection methods, it has the advantages of high throughput, high sensitivity, low sample usage, and high automation.

[0062] In one embodiment of the present invention, there is provided a use of an anti-HDGFL1 antibody as a biomarker for characterizing idiopathic inflammatory myopathy in MSA-negative IIM patients in the preparation of products related to the diagnosis of idiopathic inflammatory myopathy.

[0063] In one embodiment of the present invention, there is provided a use of an anti-HDGFL1 antibody detection agent in the preparation of a diagnostic product for diagnosing idiopathic inflammatory myopathy, assessing the prognosis of patients with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy.

[0064] Anti-HDGFL1 antibodies can be used as biomarkers for idiopathic inflammatory myopathy for the diagnosis, prognosis assessment or disease typing of idiopathic inflammatory myopathy. Therefore, by detecting anti-HDGFL1 antibodies, idiopathic inflammatory myopathy can be diagnosed, prognosis assessed or disease typing can be performed.

[0065] Furthermore, products related to the diagnosis of idiopathic inflammatory myopathy include at least one of reagents, kits, and chips.

[0066] In one embodiment of the present invention, there is provided an anti-HDGFL1 antibody detection agent for use in preparing a diagnostic product for diagnosing idiopathic inflammatory myopathy, assessing the prognosis of a patient with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy by the following method, the method specifically comprising the following steps:

[0067] Provide a serum sample from the individual to be tested;

[0068] The levels of anti-HDGFL1 antibodies in serum samples were measured;

[0069] According to the measured anti-HDGFL1 antibody level, diagnosis, prognosis assessment or disease typing is performed on the individual to be tested;

[0070] Among them, diagnosing the individual to be tested refers to determining whether the individual to be tested is an MSA-negative IIM patient; prognostic evaluation of the individual to be tested refers to evaluating the prognosis of MSA-negative IIM patients; disease typing of the individual to be tested refers to evaluating the clinical phenotype of MSA-negative IIM patients and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0071] In the present invention, diagnosing the individual to be tested refers to judging whether the individual to be tested is an MSA-negative IIM patient based on the expression level of anti-HDGFL1 antibodies in the individual's serum; or, in the case where the individual to be tested is diagnosed as an MSA-negative IIM patient, after treatment, the prognosis of myositis is accurately and reliably evaluated based on the degree of relief, alleviation, deterioration, progression, etc. of myositis symptoms, thereby providing a certain theoretical basis for further treatment and rehabilitation; or, in the case where the individual to be tested is diagnosed as an MSA-negative IIM patient, based on the different expression levels of anti-HDGFL1 antibodies, combined with the clinical symptom phenotype and the genotyping of the myositis disease, the correlation between the expression of anti-HDGFL1 antibodies and the clinical symptom phenotype and the genotyping of the myositis disease is determined, thereby providing a theoretical basis for targeted target therapy for different types of myositis diseases.

[0072] In the present invention, the prognosis of MSA-negative IIM patients refers to the degree of relief, alleviation, aggravation, progression, etc. of myositis symptoms.

[0073] In the present invention, the anti-HDGFL1 antibody detection agent refers to any compound, composition, solution, etc. that can detect the expression of anti-HDGFL1 antibodies in vivo, in vitro or in vitro. For example, the anti-HDGFL1 antibody detection agent includes reagents for detecting the expression of anti-HDGFL1 antibodies and their expression levels by immunofluorescence assay, radioimmunoassay, colloidal gold method, antibody screening, complement fixation, enzyme-linked immunosorbent assay, etc. For example, the anti-HDGFL1 antibody detection agent can capture the anti-HDGFL1 antibodies in the serum sample of the individual to be detected to form a detection agent coupled with the anti-HDGFL1 antibodies, and the second antibody can bind to the anti-HDGFL1 antibodies, thereby finally forming a detection agent-anti-HDGFL1 antibody-second antibody complex. Since the second antibody itself can be detected or carries a group that can be detected, or can react with other substrates to obtain a detectable product, the anti-HDGFL1 antibody level in the serum sample of the individual to be detected can be obtained by quantitatively detecting the second antibody. Here, the anti-HDGFL1 antibody level can refer to the presence or absence of anti-HDGFL1 antibodies, or the level of anti-HDGFL1 antibodies.

[0074] The individual to be detected may be an IIM individual or a non-IIM individual, which is also understandable to those skilled in the art.

[0075] In the present invention, the methods of obtaining serum samples, incubation, washing and detection are conventional methods in the field of biological detection. Those skilled in the art can diagnose idiopathic inflammatory myopathy, evaluate the prognosis of idiopathic inflammatory myopathy patients or determine the typing of idiopathic inflammatory myopathy by detecting the level of anti-HDGFL1 antibodies by conventional technical methods in the art, when it is known that anti-HDGFL1 antibodies can be used as biomarkers for idiopathic inflammatory myopathy. This is achievable for those skilled in the art. For example, in a specific embodiment of the present invention, anti-HDGFL1 antibodies are detected by immunoblotting.

[0076] In one embodiment of the present invention, a device / system for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of a patient with idiopathic inflammatory myopathy, or determining the classification of idiopathic inflammatory myopathy is provided, comprising:

[0077] A sample acquisition module, which is used to provide a serum sample from an individual to be tested;

[0078] A sample detection module, which is used to determine the level of anti-HDGFL1 antibodies in a serum sample;

[0079] An analysis and evaluation module, which is used to diagnose, evaluate the prognosis or perform disease typing on the individual to be tested according to the determined level of anti-HDGFL1 antibodies;

[0080] Among them, diagnosing the individual to be tested means determining whether the individual to be tested is an MSA-negative IIM patient;

[0081] Among them, the prognostic evaluation of the individual to be tested refers to the evaluation of the prognostic status of patients with MSA-negative IIM;

[0082] Among them, disease typing of the individual to be tested refers to evaluating the clinical phenotype of MSA-negative IIM patients and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0083] The present invention can simply, quickly and accurately determine whether the individual to be detected is an IIM individual or a non-IIM individual through the mutual cooperation of the sample acquisition module, the sample detection module and the analysis and evaluation module, thereby achieving the purpose of diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of idiopathic inflammatory myopathy patients or determining the typing of idiopathic inflammatory myopathy.

[0084] In one embodiment of the present invention, a computer-readable storage medium is provided, on which a computer program is stored. When the computer program is executed by a processor, the above-mentioned device / system is implemented.

[0085] In one embodiment of the present invention, a method for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of a patient with idiopathic inflammatory myopathy, or determining the classification of idiopathic inflammatory myopathy is provided:

[0086] Provide a serum sample from the individual to be tested;

[0087] The levels of anti-HDGFL1 antibodies in serum samples were measured;

[0088] According to the measured anti-HDGFL1 antibody level, diagnosis, prognosis assessment or disease typing is performed on the individual to be tested;

[0089] Among them, diagnosing the individual to be tested means determining whether the individual to be tested is an MSA-negative IIM patient;

[0090] Among them, the prognostic evaluation of the individual to be tested refers to the evaluation of the prognostic status of patients with MSA-negative IIM;

[0091] Among them, disease typing of the individual to be tested refers to evaluating the clinical phenotype of MSA-negative IIM patients and determining the correlation between anti-HDGFL1 antibodies and the clinical phenotype.

[0092] In one embodiment of the present invention, a diagnostic composition for idiopathic inflammatory myopathy is provided, comprising an anti-HDGFL1 antibody detection agent, and specifically, the diagnostic composition further comprises a pharmaceutically acceptable excipient or carrier.

[0093] In one embodiment of the present invention, a diagnostic kit for idiopathic inflammatory myopathy is provided, comprising an anti-HDGFL1 antibody detection agent, an auxiliary agent and an instruction manual.

[0094] The kit may also include any type of anti-HDGFL1 antibody detection agent described above.

[0095] The technical solution of the present application will be further explained below in conjunction with specific embodiments.

[0096] For ease of understanding, the relevant technical terms involved in the embodiments of the present application are first explained and illustrated. TM The human proteome chip is currently the largest human protein chip, containing the largest number of full-length human proteins (including 21,283 species) on a single slide. The full-length human proteins on the chip are purified from the eukaryotic model organism yeast expression system, retaining their native conformation and post-translational modifications such as phosphorylation and glycosylation. Each expressed protein contains a GST tag, which can be used for quality control detection with an Anti-GST antibody. TM The human proteome chip comes from the CDI laboratory of Johns Hopkins University in the United States.

[0097] In addition, the experimental methods in the following examples without specifying specific conditions are usually carried out under conventional conditions or conditions recommended by the manufacturers. The reagents used are commercially available or available from public channels unless otherwise specified.

[0098] Example 1: Screening of biomarkers

[0099] (1) Obtaining serum samples: 24 patients with MSA-negative myositis were used as the MSA-negative group (MSA-), 15 patients with MSA-positive myositis were used as the MSA-positive group, 15 patients with systemic lupus erythematosus (SLE) and 15 patients with systemic sclerosis (SSc) were used as the autoimmune control group, and 15 healthy subjects were used as the healthy control group (HC). The serum samples of 5 patients in each group were mixed to obtain a five-mixed serum sample, the total volume of which was 30 μl, of which the serum samples of the 5 patients were 6 μl each.

[0100] (2) Chip preprocessing: HuProt TM The human proteome chip was taken out of the -80°C refrigerator and put into a 4°C refrigerator for recovery. One day later, the proteome chip was taken out of the 4°C refrigerator and placed at room temperature for recovery and equilibrium for 1 hour. The proteome chip was taken out and placed in an incubation box, and 6 ml of a 3% bovine serum albumin solution (BSA) was added as a blocking solution, and the chip was blocked for 1 hour at 25°C using a shaker.

[0101] (3) Chip quality assessment: After blocking, the blocking solution was discarded, and the anti-GST antibody was used to hybridize with the proteome chip to verify the number of effective protein spots on the proteome chip and the correlation of signal intensity between parallel protein spots.

[0102] (4) Chip incubation: After quality assessment, the proteome chip was washed to remove the residual reagents, and then a total volume of 30 μl of five-mixed serum samples was added, incubated at 25°C for 2 hours, and washed 5 times with a 0.2% TBST solution as a washing solution. After the last wash, the washing solution was quickly discarded, and 6 ml of Alexa 647-labeled goat anti-human IgG diluted 500 times with a 3% BSA solution was added, and incubated at 25°C in the dark for 1 hour. After the incubation, the chip was washed 4 times with a 0.2% TBST solution as a washing solution, and then washed 3 times with ultrapure water.

[0103] (5) Chip detection: Place the proteome chip in a dark place to dry, read the fluorescence signal in the GenePix 4000 chip scanner and GenePix Pro software, and save the Tiff image. The scanner parameters are set as follows: the photomultiplier tube (PMT) is set to 600, the scanning intensity (ScanPower) is set to 10, and the scanning pixel is 10 μm.

[0104] (6) Data processing: According to the Tiff image of step (4) and the target protein coated array list of the proteome chip, the analysis software GenePix Pro is used to complete the pixel segmentation and extraction of each protein signal according to the protein point matrix parameters in the proteome chip. At the same time, the signal intensity of the signal points corresponding to all protein points on the chip is manually screened one by one, and the signal is extracted for further analysis to obtain the detection signal and relative quantitative basis. The signal value corresponding to the target protein is the average signal-to-noise ratio (SNR) of the signal values ​​of two parallel points (F635medium / B635medium). When this value is greater than 2, it is determined that the autoantibody against the target protein can be detected. The cut-off point of each target protein is the mean+3SD of the signal value (F635mean) of the healthy control group, and the information of the positive rate of the immune reaction of each target protein on the proteome chip is calculated. The chip significance analysis is performed using high-throughput bioinformatics analysis tools to analyze the information of differential proteins between groups, and the candidate target proteins are selected with a q value less than 5% and a Fold change greater than 3.

[0105] Through the above analysis and screening, 118 candidate target proteins were obtained. The specific target antigen names can be found in Table 1. Among them, the distribution of the top 50 candidate target proteins in descending order of fold change in each group is as follows: Figure 1 As shown in Figure 1, it can be found that the HDGFL1 protein has a significantly high signal (SNR value) in the MSA negative group (MSANeg), while the signal is lower in other groups. Combined with the signal value corresponding to the target protein on the proteome chip, as shown in Figure 1 Figure 2 As shown, it can be found that the HDGFL1 protein has a significantly high signal in the MSA negative group (MSA-), while the signal is low in the healthy control group (HC), indicating that the anti-HDGFL1 antibody has the potential to be used as a biomarker for identifying patients with idiopathic inflammatory myopathy.

[0106] Table 1

[0107] SMCO3 EXOSC7 HK1 HDGFL1 THOP1 FERMT2 TXNDC2 DPY30 GSN NANP KLHL7 OTUD5 PARP1 OGD MAGI1 KJ898030 BPIFA1 ENPP3 QPRT GAD2 C9orf142 VWA8 QUR POLB TPRX1 PGK1 BZW2 CAP1 DAPP1 THUMPD1 NUDT14 HGFAC MYK PTMA C10orf25 N4BP1 COQ9 CDKN2C MAGEL2 LIPN Prdm9 TAF10 PRMT3 UBL3 HGS DMRT2 PLEKHM2_frag ITIH3 ZNF746 SUOX NRG3 FAM21A MAGEC2 ROPN1 DNAJB4 RAD23A GOT1 ACTN1 TXLNB MVK MYCL RPL18A A0jn7 ERICH5 NDEL1 PRMT7 BABAM1 ALOXE3 FAM29A TMEM163 VCP CAPRIN1 ELANE MESP2 TP53TG1 ZNF768 STAT4 TLK2 DGK RBM24 RLN3 PRY TYMP E2F4 CLDN2 HBE1 ULBP2 IGLL5 NADSYN1 NVL PROL1 ZNF696 SASS6 ENPP4 GPD1 TRAP1 GCHFR TMX4 KLC2 KLHL26 BAX SLC1A5 PPP5C WASF2 RIMBP3_frag GDI2 RPL36AL SESN2 TCF24 SNX16 TSPYL6 SH3BGR AHCY NKX2-6 SEPHS1 AVP MLXIP UGT1A4

[0108] Example 2: Validation of Screened Biomarkers

[0109] (1) Obtaining serum samples: Serum samples from 42 patients with MSA-negative myositis were obtained as the MSA-negative group (MSA - ), and sera from 149 patients with MSA-positive myositis were obtained as the MSA-positive group (MSA + ), sera from 21 patients with systemic lupus erythematosus and 20 patients with systemic sclerosis were obtained as the autoimmune disease control group, and sera from 73 healthy subjects were obtained as the healthy control group (HC).

[0110] (2) Immunoblotting: Mix 20 μl, 0.75 μg / μl recombinant HDGFL1 protein with 60 μl SDS-PAGE protein loading buffer (5×) and 220 μl PBS, boil at 100°C for 10 minutes, and then add it to the prepared gel for SDS-PAGE electrophoresis. After the electrophoresis, the protein in the gel is electrotransferred to the polyvinylidene fluoride membrane. Block the polyvinylidene fluoride membrane with successful transfer for 2 hours, add the serum sample in step (1), incubate on a shaker for 2 hours, wash, add horseradish peroxidase (HRP)-labeled goat anti-human IgG, and finally detect the fluorescence signal with a fluorescence imager. The appearance of the target band indicates a positive result, and the absence of the target band indicates a negative result. The specific band image can be seen Figure 3 The statistical results of the bands can be seen in Table 2.

[0111] like Figure 3 As shown in Table 2, anti-HDGFL1 antibodies can be detected in the MSA negative group, but not in the healthy control group. As shown in Table 2, the validation of the biomarker in the expanded population showed that the positive rate was 33.3% in the MSA negative group, 17.4% in the MSA positive group, 0 in the healthy control group, and 24.4% in the autoimmune control group. This shows that 33.3% of MSA negative myositis patients have anti-HDGFL1 antibodies in their sera, while no healthy people have anti-HDGFL1 antibodies in their sera, indicating that anti-HDGFL1 antibodies can be used as a biomarker to characterize patients with idiopathic inflammatory myopathy. In addition, the positive rate of anti-HDGFL1 antibodies in MSA negative patients is about twice that of MSA positive patients. Therefore, for MSA negative patients, when the currently known myositis specific autoantibodies as biomarkers cannot diagnose patients with idiopathic inflammatory myopathy, anti-HDGFL1 antibodies can be used as a supplementary biomarker for the diagnosis and prognosis of idiopathic inflammatory myopathy.

[0112] Table 2

[0113] Group Total number of samples Positive samples (pcs) Positive rate (%) MSA negative group 42 14 33.3% Healthy control group 73 0 0% MSA positive group 149 26 17.4% Autoimmune disease control group 41 10 24.4%

[0114] In summary, the anti-HDGFL1 antibody of the present invention can be used as a biomarker for characterizing idiopathic inflammatory myopathy, and can be used for the diagnosis, prognosis evaluation and disease typing of idiopathic inflammatory myopathy. At the same time, the biomarker can be used as a supplementary diagnostic biomarker when MSA cannot be used to diagnose patients with idiopathic inflammatory myopathy, that is, when MSA is negative. Therefore, the present invention helps to further identify other disease subgroups in the myositis spectrum, which is of great significance for the early diagnosis and treatment, prognosis and potential mechanism of IIM.

[0115] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that the technical solutions described in the above embodiments can still be modified, or some or all of the technical features can be replaced by equivalents. However, these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. Use of an anti-HDGFL1 antibody as a biomarker for idiopathic inflammatory myopathy.

2. The use according to claim 1, characterized in that: The use of the anti-HDGFL1 antibody as a biomarker for characterizing idiopathic inflammatory myopathy in patients with myositis-specific autoantibodies MSA-negative idiopathic inflammatory myopathy.

3. The use according to claim 2, characterized in that: The anti-HDGFL1 antibody is used as a biomarker for characterizing idiopathic inflammatory myopathy in patients with MSA-negative idiopathic inflammatory myopathy in the preparation of products related to the diagnosis of idiopathic inflammatory myopathy.

4. Use of an anti-HDGFL1 antibody detection agent in the preparation of products related to the diagnosis of idiopathic inflammatory myopathy.

5. The use according to claim 4, characterized in that: The products related to the diagnosis of idiopathic inflammatory myopathy include products for diagnosing idiopathic inflammatory myopathy, products for evaluating the prognosis of patients with idiopathic inflammatory myopathy, or products for determining the classification of idiopathic inflammatory myopathy.

6. The use according to claim 4, characterized in that: The product related to the diagnosis of idiopathic inflammatory myopathy includes at least one of a reagent, a kit, and a chip.

7. The use according to claim 4, characterized in that: The anti-HDGFL1 antibody detection agent includes a reagent for detecting the expression level of the anti-HDGFL1 antibody by at least one of immunofluorescence assay, radioimmunoassay, colloidal gold method, antibody screening, complement fixation, and enzyme-linked immunosorbent assay.

8. Use of an anti-HDGFL1 antibody detection agent in the preparation of a product for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of a patient with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy by the following method, characterized in that: The method comprises the following steps: Provide a serum sample from the individual to be tested; determining the level of anti-HDGFL1 antibodies in the serum sample; According to the determined level of anti-HDGFL1 antibodies, diagnosis, prognosis assessment or disease typing is performed on the individual to be tested; Wherein, the diagnosis of the individual to be detected refers to determining whether the individual to be detected is a patient with idiopathic inflammatory myopathy who is negative for myositis-specific autoantibodies MSA; Wherein, the prognostic evaluation of the individual to be tested refers to evaluating the prognosis of the MSA-negative idiopathic inflammatory myopathy patient; The disease typing of the individual to be tested refers to evaluating the clinical phenotype of the MSA-negative idiopathic inflammatory myopathy patient and determining the correlation between the anti-HDGFL1 antibody and the clinical phenotype.

9. A kit for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of patients with idiopathic inflammatory myopathy, or determining the typing of idiopathic inflammatory myopathy, characterized in that: Includes anti-HDGFL1 antibody detection reagent.

10. A system for diagnosing idiopathic inflammatory myopathy, evaluating the prognosis of patients with idiopathic inflammatory myopathy, or determining the classification of idiopathic inflammatory myopathy, characterized in that: include: A sample acquisition module, which is used to provide a serum sample from an individual to be tested; A sample detection module, which is used to determine the level of anti-HDGFL1 antibodies in the serum sample; An analysis and evaluation module, which is used to diagnose, evaluate the prognosis or perform disease typing on the individual to be tested according to the determined level of anti-HDGFL1 antibodies; Wherein, the diagnosis of the individual to be detected refers to determining whether the individual to be detected is a patient with idiopathic inflammatory myopathy who is negative for myositis-specific autoantibodies MSA; Wherein, the prognostic evaluation of the individual to be tested refers to evaluating the prognosis of the MSA-negative idiopathic inflammatory myopathy patient; Wherein, determining the disease typing of the individual to be tested refers to evaluating the clinical phenotype of the MSA-negative idiopathic inflammatory myopathy patient and determining the correlation between the anti-HDGFL1 antibody and the clinical phenotype.

Citation Information

Patent Citations

  • Nonradioactive detecting methods of inflammatory myopathy HMGCR (3-hydroxy3-methylutaryl coenzyme A reductase) autoantibody and application

    CN106596975A

  • Biomarker for detecting idiopathic inflammatory myopathies and application of biomarker

    CN108761067A

  • Methods for identifying candidate biomarkers

    CN110168370A

  • Molecular marker for diagnosing idiopathic inflammatory myopathy and application thereof

    CN110275026A

  • Application of Con A agglutinin in preparation of reagent for diagnosing anti-Jo 1 antibody negative idiopathic inflammatory myositis

    CN110865190A

Cited By

  • RNA composition for diagnosing or evaluating idiopathic inflammatory myopathy, kit and application

    CN120485358A

  • RNA composition for diagnosing idiopathic inflammatory myopathy or evaluating treatment of idiopathic inflammatory myopathy, kit and application thereof

    CN120536569A